Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 4

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 8Thoracic 4Head & Neck 4Gynecologic 4Lymphoid 3Dermatologic 3Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2CNS 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thymoma 1Lung Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × NVP-BKM120 × Thoracic × Clear all
NCT02220855 2022-04-11

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

Indiana University

Phase 2 Completed
14 enrolled 14 charts
Thoracic

Thymoma

NCT01487265 2019-03-06

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

SCRI Development Innovations, LLC

Phase 2 Completed
37 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01297491 2016-03-11

BASALT-1

Novartis

Phase 2 Completed
63 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡